Methods: Simultaneous single photon emission CT scan (20 mCi technetium Tc 99m stress/rest sestamibi) and echocardiography (second harmonic imaging) during a two-step (0.56 to 0.84 mg/kg) dipyridamole infusion protocol. Two sestamibi readings were performed. The first reading considered only those studies with reversible defects (sestamibi-1) to be positive. The second reading considered those studies with any defect (sestamibi-2) to be positive. CAD was defined as a > 50% reduction in diameter in at least one major vessel seen on coronary angiography. Results: CAD was present in 17 patients (31.5%). The global predictive accuracy for CAD was significantly higher for DSE (87.0%) and sestamibi-1 (79.6%) than for sestamibi-2 (57.4%) [p < 0.01 vs DSE; p < 0.05 vs sestamibi-1]. No significant differences in sensitivity were present, but specificity was significantly higher for DSE (94.6%) and sestamibi-1 (81.1%) than for sestamibi-2 (43.2%; p < 0.01 vs both the other two tests). Of 14 patients with LV dilatation, 26.8% were falsely positive for CAD (in some cases for posterior defects) as determined by sestamibi-1 and 64.3% were falsely positive for CAD by sestamibi-2 vs none by DSE. Conclusions: DSE is at least as accurate as dipyridamole sestamibi scintigraphy for predicting CAD in patients with complete LBBB and tends to be more specific in those patients with underlying LV dilatation.
M
yocardial perfusion scintigraphy often is performed to detect coronary artery disease (CAD) in patients with left bundle-branch block (LBBB). However, stress scintigraphy is not specific for the frequent occurrence of septal, anterior, and apical defects in the absence of CAD. This diagnostic challenge can be reduced but not eliminated using dipyridamole as a stress agent instead of exercise. 1, 2 To our knowledge, only a few studies 3, 4 have compared echocardiography with myocardial perfusion scintigraphy during dobutamine infusion in patients with LBBB, and, so far, none has compared them during dipyridamole infusion. Accordingly, we analyzed simultaneous dipyridamole stress echocardiography (DSE) and sestamibi myocardial perfusion scintigraphy in a group of patients with complete LBBB and intermediate pretest probability of CAD. 5 
Materials and Methods

Patients and Protocol
From January to June 1999, we examined 58 consecutive patients with complete LBBB 6 and chest pain. Patients who had experienced previous myocardial infarction, unstable angina, or had previously documented CAD were excluded. Other criteria of exclusion were recent pulmonary edema, severe arterial hypertension, ventricular tachyarrhythmias, atrial fibrillation, contraindications to dipyridamole infusion, 7 and technically suboptimal echocardiograms (four patients). The final study group consisted of 54 patients (26 men and 28 women) with a mean (Ϯ SD) age of 59 Ϯ 7 years. The mean pretest probability of CAD in the study patients, which was calculated from age, gender, and chest pain characteristics, was 61 Ϯ 2%. 5 DSE and sestamibi scintigraphy values were obtained simultaneously under BP and 12-lead ECG monitoring and after discontinuation of all anti-ischemic drugs. A two-step (0.56 to 0.84 mg/kg) dipyridamole infusion protocol was used. The end points were the following: achievement of dipyridamole peak dose; angina; severe hypertension or hypotension; significant ventricular or supraventricular arrhythmias; or new dyssynergy. Technetium Tc 99m sestamibi was injected at the end of the dipyridamole infusion. All patients underwent coronary angiography within 7 days of the echocardiographic and scintigraphic studies. Significant CAD was defined as a Ն 50% reduction in diameter of at least one major vessel.
DSE
A second harmonic imaging procedure was performed in all patients (Sonos 5500 System; Hewlett-Packard; Andover, MA). Studies were digitized in a quad-screen format and were analyzed by two investigators who were blinded to each other's data. The left ventricular (LV) end-diastolic internal dimension was measured by M-mode. The LV ejection fraction was calculated as the mean from 4-chamber and 2-chamber apical views (area-length method). Patients with an LV end-diastolic internal dimension of Ͼ 60 mm were considered to have LV dilatation. The LV was divided into 16 segments, according to the guidelines of the American Society of Echocardiography. 8 Segments tributary of the right and circumflex coronary artery constituted the posterior region. The other segments, including an isolated apical abnormality, constituted the anterior region. Both endocardial shortening and wall thickening were analyzed in all segments, including the ventricular septum. Normal septal motion was considered to be present when, apart from early paradoxical systolic movement, (relatively) normal posterior shortening and thickening were evident in systole. 9 A wall motion score index was calculated using a 4-point scale (1, normal; 4, dyskinetic). A study was considered to be positive in the presence of a new or worsening wall motion abnormality in one or more segment of one region. The condition of akinesia becoming dyskinesia was not considered. 10 The intraobserver and interobserver variabilities for segmental readings in our laboratory were 2.6% and 3.6%, respectively.
Sestamibi
Stress/rest single photon emission CT was performed (20 mCi Tc 99m sestamibi). Short-axis, horizontal long-axis, and vertical long-axis slices were acquired and were interpreted by two investigators who were blinded to each other's data. The LV was divided into 16 segments which were attributed to the anterior or posterior region, as for echocardiography. Only vertical and horizontal long-axis slices were used to define the apex. Sestamibi uptake was visually evaluated with the assistance of a circumferential profile analysis. Segmental uptake was classified using a 4-point scale (normal, 0; equivocal or minimally reduced, 1; moderately reduced, 2; severely reduced, 3). Studies were considered to be positive only in the presence of reversible defects (sestamibi-1) or, alternatively, in the presence of any grade-2 to grade-3 defect in at least one segment of one region (sestamibi-2). 3 The intraobserver and interobserver variabilities for sestamibi segmental readings in our laboratory were 2.1% and 2.6%, respectively.
Statistical Analysis
When appropriate, paired and unpaired t tests and 2 tests were used. The predictive accuracy for predicting CAD of DSE, sestamibi-1, and sestamibi-2 was compared by the Cochran Q test. The same test also was applied to separately compared true-positive results (sensitivity) and true-negative results (specificity) for each diagnostic test. 
Results
General Data
CAD was present in 17 patients (31.5%), 12 of whom had one-vessel CAD, 2 of whom had twovessel CAD, and 3 of whom had three-vessel CAD. LV dilatation was present in 2 patients with CAD (11.7%) and in 12 patients without CAD (32.4%). Patients with and without CAD were not significantly different as regards gender, age, and prevalence of diabetes, hypertension, or hypercholesterolemia. At baseline echocardiography, the mean (Ϯ SD) LV end-diastolic internal dimension and the ejection fraction were 54 Ϯ 8 mm and 45 Ϯ 11%, respectively. Septal akinesia or dyskinesia was found in three patients with CAD (17.6%) and in seven patients without CAD (18.9%; difference between the two groups was not significant [NS]).
Dipyridamole Test Effects
Three patients (5.6%) received only the first dose of dipyridamole because of new or worsening wall motion abnormalities. Four patients (7.4%) complained of chest pain during the second dose of dipyridamole. From baseline to the dipyridamole peak dose, heart rate increased from 76 Ϯ 11 to 93 Ϯ 13 beats/min (p Ͻ 0.01), systolic BP increased from 126 Ϯ 16 to 127 Ϯ 13 mm Hg (NS), diastolic BP increased from 81 Ϯ 6 to 80 Ϯ 5 mm Hg (NS), the rate-systolic BP product increased from 9,589 Ϯ 1,580 to 11,736 Ϯ 1,740 (p Ͻ 0.01), and the echocardiographic wall motion score index increased from 1.4 Ϯ 0.3 to 1.5 Ϯ 0.4 (p Ͻ 0.001).
Diagnostic Performance of DSE, Sestamibi-1, and Sestamibi-2
The diagnostic performances of DSE, sestamibi-1, and sestamibi-2 in study group patients is shown in Table 1 and Figure 1 (separate data for anterior and posterior regions).
The global predictive accuracy for CAD was significantly higher for DSE (87.0%) and sestamibi-1 (79.6%; NS between these two tests) than for sestamibi-2 (57.4%; p Ͻ 0.01 vs DSE; p Ͻ 0.05 vs sestamibi-1). A separate analysis revealed no significant differences among the three diagnostic tests in terms of sensitivity (70.6%, 76.5%, and 88.2%, respectively; p ϭ 0.17), most probably because of the low number of patients with CAD, whereas specificity was significantly higher for DSE (94.6%) and sestamibi-1 (81.1%; NS between these two tests) than for sestamibi-2 (43.2%; p Ͻ 0.01 vs both the other two tests).
DSE tended to be more accurate than both sestamibi-1 and sestamibi-2 in the 14 patients with underlying LV dilatation (Table 2 ). In fact, 26.8% and 64.3% of patients, respectively, had falsely positive responses to sestamibi-1 and sestamibi-2 and no falsely positive responses to DSE (Fig 2) . Remarkably, there were three reversible falsely positive posterior defects.
Agreement Among DSE, Sestamibi-1, and Sestamibi-2
Forty-two patients (78%) had concordant DSE and sestamibi-1 responses (, 0.49; 95% CI, 0.25 to 0.72). Of 12 patients (22%) with discordant DSE and sestamibi-1 responses, 9 had positive responses on scintigraphy (7 false-positive responses). We found 30 patients (55%) with concordant DSE and sestamibi-2 responses (, 0.23; 95% CI, 0.06 to 0.42). Of 24 patients (45%) with discordant DSE and sestamibi-2 responses, 23 had positive responses on scintigraphy (20 false-positive responses).
Discussion
In a group of patients with complete LBBB and intermediate pretest probability of CAD, DSE was at least as accurate as dipyridamole sestamibi-1 and was definitely more accurate than dipyridamole sestamibi-2 in predicting obstructive CAD. Our data confirmed that myocardial perfusion scintigraphy has limited value in this setting. In fact, when dipyridamole sestamibi was utilized to compare nuclear and echocardiographic methods directly under the same stress agent and to perform delayed scintigraphic acquisitions without interference from echocardiographic recordings, we did not observe any reduction of the commonly reported scintigraphic false-positive responses. 1, 2, [11] [12] [13] [14] Most fixed defects and many reversible defects of the basal and midportion of the septum occurred, in fact, in patients without CAD. Thus, sestamibi-2 turned out to be quite nonspecific for CAD, and we think that it should be definitively abandoned as a reading method in the presence of complete LBBB. However, sestamibi-1 also was not very specific, although the reversible septal defects noticed in the absence of CAD may derive from true ischemia due to microcirculatory dysfunction, 15, 16 and not simply from dipyridamole-induced flow heterogeneity. 17 DSE was very specific for CAD and, although it is less sensitive than sestamibi scintigraphy for onevessel disease and in our patients with complete LBBB, it demonstrated an accuracy not inferior to that found in patients without LBBB. 17 This good diagnostic performance of DSE was not anticipated. In fact, the evaluation of stress-induced contractile changes in patients with LBBB traditionally has been difficult to discern even for the experienced observer due to the presence of various degrees of anteroseptal asynergy at rest, which in some cases mimics the effects of an extensive anteroseptal infarction. 18 However, regional wall motion analysis by echocar- diography has been substantially facilitated by modern technology, such as second harmonic imaging. 19 In fact, the endocardial border can be optimally imaged in most cases even at the level of the distal portion of the anterior and septal wall, as well as of the entire apex. Further imaging improvement can be achieved in the near field through the fine regulation of gain and focus settings. Modern computerized tools, such as color kinesis, may improve this approach. Moreover, septal motion can be more confidently evaluated by combining M-mode and two-dimensional echocardiographic analysis, as demonstrated by the recent data from the study by Geleijnse et al. 9 Thus, giving particular attention also to the contractile behavior of the apex, a biphasic response suggesting inducible ischemia in the anterior region can be diagnosed even in patients showing severe LBBB-linked asynergy at baseline. A new finding in our study with possible practical implications was that two thirds of patients with LBBB and underlying LV dilatation who were examined by sestamibi-2 and one third of patients with LBBB and underlying LV dilatation who were examined by sestamibi-1 had false-positive responses for CAD, compared with no false-positive responses when patients were examined by DSE. Remarkably, in these patients we observed some very misleading falsely positive posterior defects, which were similar to those noticed in patients with LV hypertrophy and/or dilatation 20 -22 and had been attributed to microcirculatory dysfunction or to partial volume effect. However, the cause of these defects in the presence of complete LBBB and LV dilatation remains unclear. Some important limitations of our study should be acknowledged. First of all, the population examined was relatively small, particularly regarding patients with underlying LV dilatation. Consequently, our dismissal of scintigraphy in this subset of patients should be confirmed with a larger group of patients. Furthermore, we did not use new scintigraphic techniques that allow the combined analysis of myocardial perfusion and wall motion, 23 which might have provided better results than those found in this study. Finally, different results might have been observed in an LBBB population with different pretest probabilities for CAD.
In conclusion, our data show that echocardiography during dipyridamole infusion is at least as accurate as dipyridamole myocardial perfusion scintigraphy for predicting CAD in patients with LBBB and suggest that DSE may be particularly appropriate in patients with underlying LV dilatation.
